# Savara, Inc. (SVRA) Stock Analysis: A Promising Biotech with an 87% Potential Upside

- Link: https://www.directorstalkinterviews.com/savara-inc-svra-stock-analysis-a-promising-biotech-with-an-87-potential-upside/4121234181
- Published: 2026-01-09T11:28:43+00:00
- Author: Madison Wilson

Investors are turning their attention towards Savara, Inc. (NASDAQ: SVRA), a clinical-
stage biopharmaceutical company specializing in rare respiratory diseases. With 
its market capitalization standing at $1.17 billion, Savara offers an intriguing
investment opportunity within the healthcare sector, particularly in the biotechnology
industry. The company is headquartered in Langhorne, Pennsylvania, and its primary
focus is on developing treatments for rare respiratory conditions.

Savara’s lead product candidate, molgramostim, is currently in Phase 3 development
for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). This innovative
approach has the potential to address unmet needs in the treatment of this rare 
respiratory condition, providing a significant growth catalyst for the company.

Despite its promising pipeline, Savara’s financial metrics present a mixed picture.
The company is trading at $5.76 per share, with a 52-week range of $1.94 to $6.94.
The stock has shown resilience, maintaining its current price without significant
fluctuation recently. However, Savara’s forward P/E ratio of -14.40 and an EPS of-
0.53 highlight the typical challenges faced by clinical-stage biotechs, which often
operate at a loss during the development phase.

The company’s return on equity (ROE) stands at -78.74%, and it has reported a free
cash flow of -$55.26 million, indicating a heavy investment in research and development,
which is critical for a successful Phase 3 trial outcome. Savara’s dividend yield
remains non-existent as the company prioritizes reinvestment over shareholder payouts,
reflecting a payout ratio of 0.00%.

From an analyst perspective, Savara enjoys a favorable outlook, with 8 buy ratings
and no hold or sell recommendations. This optimism is supported by an average target
price of $10.81, suggesting a substantial potential upside of 87.72% from the current
trading price. The target price range spans from $9.00 to $16.00, highlighting the
broad spectrum of analyst expectations based on the company’s future performance
and trial results.

Technical indicators provide additional insights into the stock’s performance. The
50-day moving average is at $5.43, while the 200-day moving average is significantly
lower at $3.57, indicating a positive upward trend. The RSI (14) of 47.22 suggests
that the stock is neither overbought nor oversold, while the MACD of 0.04 and a 
signal line of 0.18 suggest a neutral momentum in the stock’s price movement.

As Savara progresses with its clinical trials and continues to focus on its lead
product candidate, investors should monitor the company closely. The potential success
of molgramostim in Phase 3 trials could act as a significant catalyst, driving up
the stock’s value and fulfilling the analyst’s optimistic price targets. For investors
seeking exposure to innovative biotech ventures with considerable upside potential,
Savara, Inc. presents a compelling opportunity.

Share on: